Dr. David Weinstein is a leading expert in pediatric endocrinology and gene therapy. After graduating from Harvard Medical School in 1994, he completed his residency, chief residency, and fellowship at Boston Children’s Hospital, specializing in pediatric endocrinology. He later earned a Master's in Clinical Investigation from Harvard and MIT. Dr. Weinstein directed the Glycogen Storage Disease Program at Boston Children’s Hospital and then at the University of Florida, where he became a tenured professor. In 2017, he moved to the University of Connecticut, launching the world’s first gene therapy trial for glycogen storage disease.

In 2020, Dr. Weinstein transitioned to the biotech industry, serving as Senior Vice President and Medical Lead for GM1 gangliosidosis and metachromatic leukodystrophy gene therapy trials at Passage Bio. He later served as Acting Chief Medical Officer for Grace Science, LLC, leading the submission of the IND for gene therapy for NGLY1 deficiency. Currently, he consults on rare disease trials and serves on several scientific advisory boards, including the Association for Glycogen Storage Disease and the Cure GM1 Foundation. Dr. Weinstein has received numerous accolades, including the inaugural Goldwater Scholarship, the Jan Albrecht Award, the George Sacher Award, and the Order of the Smile international humanitarian award.